A New Solution to Accelerate Homology-Directed Repair in Genome Editing
News from Integrated DNA Technologies
In a press release today, Integrated DNA Technologies (IDT) announces the addition of Alt-R HDR Donor Blocks to its complete portfolio of Alt-R™ CRISPR genome-editing solutions.
The new product makes it possible for scientists to quickly obtain synthetic DNA donor templates of up to 3 kb in length for CRISPR-based knock-in experiments that rely on homology-directed repair (HDR). Alt-R HDR Donor Blocks are chemically modified to improve HDR rates and prevent the undesirable, non-homologous integration events often seen with unmodified, linear double-stranded DNA templates.
Studies performed by IDT revealed that the use of Alt-R HDR Donor Blocks resulted in the highest HDR rates in CRISPR experiments when compared to unmodified dsDNA or long ssDNA.
Read the full press release from IDT here.
About Integrated DNA Technologies
Integrated DNA Technologies, Inc. develops, manufactures, and markets nucleic acid products for the life sciences industry in the areas of academic and commercial research, agriculture, medical diagnostics, and pharmaceutical development. IDT has developed proprietary technologies for genomics applications such as next generation sequencing, CRISPR genome editing, synthetic biology, digital PCR, and RNA interference. Through its GMP services, IDT manufactures products used by scientists researching many forms of cancer and most inherited and infectious diseases. IDT is widely recognized as the industry leader in custom nucleic acid manufacture, serving over 130,000 life sciences researchers. IDT was founded in 1987 and has its manufacturing headquarters in Coralville, Iowa, USA, with additional manufacturing sites in San Diego, California, USA; Research Triangle Park, North Carolina, USA; Ann Arbor, Michigan, USA; Leuven, Belgium; and Singapore. For more information, please visit www.idtdna.com and follow on Twitter, LinkedIn, Facebook, YouTube, and Instagram.
Arsenal Biosciences, Inc.
Cure Rare Disease, Inc